To comprehensively clarify the role of Asprosin in NAFLD, Asprosin expression was further tested in PA‐treated AML‐12 cells and Asprosin was found to be overexpressed with the increasing time of PA treatment. This evidence concerns the gene FBN1 and metabolic dysfunction-associated steatotic liver disease.